Results 61 to 70 of about 3,811,568 (245)

Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy

Advanced Healthcare Materials, EarlyView.
Prostate patient‐derived organoids (PDOs) were established from TURP and biopsy specimens with >90% success and retain key features of their tissues of origin, making them functional avatars for antisense oligonucleotide (ASO) therapy . Transfecting single cells outside the Matrigel matrix and then reconstituting organoids overcomes the 3D delivery ...
Thi Thom Tran, Thi Tu Uyen Phan, Michael Baboudjian, Quang Hieu Duong, Ines Sousa, Thi Thuy Le, Virginie Baylot, Sophie Giusiano, Laurent Daniel, Pauline Brige, Benjamin Guillet, Cyrille Bastide, Carmen Garrido, David Taïeb, Thi Khanh Le, Palma Rocchi   +15 more
wiley   +1 more source

Gene amplifications associated with the development of hormone- resistant prostate cancer [PDF]

, 2003
Purpose: Hormone resistance remains a significant clinical problem in prostate cancer with few therapeutic options. Research into mechanisms of hormone resistance is essential.
Krishnan, S., Witton, C.J., Edwards, J., Bartlett, J.M.S.   +3 more
core   +5 more sources

Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer

Pharmaceutics, 2021
There have been several studies that have linked elevated scavenger receptor class b type 1 (SR-B1) expression and activity to the development and progression of castration-resistant prostate cancer (CRPC).
Mitali Pandey, Grace Cuddihy, Jacob A. Gordon, Michael E. Cox, Kishor M. Wasan   +4 more
doaj   +1 more source

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).

, 2018
Purpose: Persistent androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic strategies to overcome this are urgently required.
Crespo, M, Sharp, A, Francis, JC, Plymate, SR, Swain, A, Carreira, S, Nava Rodrigues, D, de Bono, JS, Paschalis, A, Ning, J, Sumanasuriya, S, Hughes, A, Gil, V, International SU2C/PCF Prostate Cancer Dream Team,, Seed, G, Chinnaiyan, AM, Yuan, W, Dolling, D, Neeb, A, Knight, E, Mani, RS, Raj, GV, Figueiredo, I, Welti, J, Clarke, M, Boysen, G, Halsey, WS   +26 more
core   +1 more source

Aggressive Variants of Castration-Resistant Prostate Cancer [PDF]

Clinical Cancer Research, 2014
Abstract A subset of patients with advanced castration-resistant prostate cancer may eventually evolve into an androgen receptor (AR)–independent phenotype, with a clinical picture associated with the development of rapidly progressive disease involving visceral sites and hormone refractoriness, often in the setting of a low or modestly ...
Himisha, Beltran, Scott, Tomlins, Ana, Aparicio, Vivek, Arora, David, Rickman, Gustavo, Ayala, Jiaoti, Huang, Lawrence, True, Martin E, Gleave, Howard, Soule, Christopher, Logothetis, Mark A, Rubin   +11 more
openaire   +2 more sources

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Castrate‐resistant prostate cancer: the future of antiandrogens [PDF]

Trends in Urology & Men's Health, 2014
AbstractSeveral promising new treatment options for men with castrate‐resistant prostate cancer have become available recently. The authors look at developments in this rapidly progressing area.
Pshezhetskiy, Dmitry, Alshaker, Heba, Stebbing, Justin   +2 more
openaire   +3 more sources

DLST Succinylation‐Mediated Mitochondrial Metabolic Remodeling and Cuproptosis Resistance Promote Malignant Progression of Lung Adenocarcinoma

Advanced Science, EarlyView.
The DLST K409 succinylation mediated by CPT1A promotes OXPHOS and redox homeostasis through regulating enzyme activity, thereby promoting the malignant progression of LUAD. Notably, the succinylation of DLST can enhance the cuproptosis resistance by inhibiting its lipoylation.
Xuanxuan Li, Peijun Zhou, Xingzhi Peng, Qixin Liu, Wenhui Zeng, Rui Wang, Liangfang Shen, Jinwu Peng, Qin Zhou, Lifang Yang   +9 more
wiley   +1 more source

Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications

Therapeutic Advances in Medical Oncology, 2017
Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy.
Naoki Terada, Shusuke Akamatsu, Takashi Kobayashi, Takahiro Inoue, Osamu Ogawa, Emmanuel S Antonarakis   +5 more
doaj   +1 more source

Castration-resistant prostate cancer: systemic therapy in 2012

Clinics, 2012
Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide. It is typically diagnosed in its early stages, and the disease exhibits a relatively indolent course in most patients. Despite the curability of localized disease
Fernando C. Maluf, Oren Smaletz, Daniel Herchenhorn   +2 more
doaj   +1 more source